Hemoglobin Clinical Trials

56 recruitingLast updated: May 21, 2026

There are 56 actively recruiting hemoglobin clinical trials across 46 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include London, United Kingdom, New York, New York, United States, Minneapolis, Minnesota, United States. Updated daily from ClinicalTrials.gov.


Hemoglobin Trials at a Glance

56 actively recruiting trials for hemoglobin are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 19 trials, with the heaviest enrollment activity in London, New York, and Minneapolis. Lead sponsors running hemoglobin studies include Novartis Pharmaceuticals, Masonic Cancer Center, University of Minnesota, and National Heart, Lung, and Blood Institute (NHLBI).

Browse hemoglobin trials by phase

About Hemoglobin Clinical Trials

Looking for clinical trials for Hemoglobin? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hemoglobin trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hemoglobin clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 56 trials

Recruiting
Phase 3

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals35 enrolled11 locationsNCT07154745
Recruiting

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria, PNH
Novartis Pharmaceuticals50 enrolled10 locationsNCT07229235
Recruiting
Phase 1

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH - Paroxysmal Nocturnal Hemoglobinuria
Shanghai Lanyi Therapeutics Co., Ltd.24 enrolled2 locationsNCT07256301
Recruiting
Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Paroxysmal Nocturnal Hemoglobinuria, PNHSevere Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting
Phase 1

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Sickle Cell DiseaseHb-SS DiseaseHemoglobin S+3 more
National Heart, Lung, and Blood Institute (NHLBI)25 enrolled1 locationNCT05904093
Recruiting

Discarded Bone Marrow for Hematology Research

Hemoglobinopathies
St. Jude Children's Research Hospital50 enrolled1 locationNCT04671212
Recruiting
Phase 1Phase 2

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Paroxysmal Nocturnal Hemoglobinuria, PNH
ADARx Pharmaceuticals, Inc.50 enrolled4 locationsNCT05876312
Recruiting

Danicopan PMS in Korea

Paroxysmal nocturnal hemoglobinuria
AstraZeneca8 enrolled4 locationsNCT07457151
Recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

PregnancyParoxysmal Nocturnal Hemoglobinuria, PNHUltomiris-exposed Pregnant/ Postpartum+3 more
Alexion Pharmaceuticals, Inc.75 enrolled7 locationsNCT06312644
Recruiting
Phase 1Phase 2

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 3

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Paroxysmal Nocturnal Hemoglobinuria, PNH
Novartis Pharmaceuticals12 enrolled13 locationsNCT06934967
Recruiting
Phase 1Phase 2

Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal nocturnal hemoglobinuria
Jiangsu Hansoh Pharmaceutical Co., Ltd.50 enrolled1 locationNCT07470762
Recruiting

Specified Drug-use Surveillance of Fabhalta Capsules

Paroxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals100 enrolled92 locationsNCT06606314
Recruiting
Phase 1

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

Paroxysmal Nocturnal Hemoglobinuria, PNHComplement-mediated Kidney Disease
Shenzhen Kangzhe Biotechnology Co., Ltd.88 enrolled1 locationNCT07462780
Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 1Phase 2

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

HemoglobinopathiesMetabolic DisordersHematologic, Immune, or Bone Marrow Disorders+1 more
Washington University School of Medicine220 enrolled28 locationsNCT00920972
Recruiting
Phase 3

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Beta-ThalassemiaSickle Cell DiseaseHematologic Diseases+4 more
Vertex Pharmaceuticals Incorporated26 enrolled6 locationsNCT05477563
Recruiting
Phase 1Phase 2

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

Paroxysmal Nocturnal Hemoglobinuria, PNHPersistent Anemia
Regeneron Pharmaceuticals24 enrolled7 locationsNCT07187401
Recruiting
Phase 3

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals202 enrolled43 locationsNCT05744921
Recruiting

Preoperative Hemoglobin and Acute Kidney Injury in Emergency Surgery

Emergency surgeryAcute Kidney InjuryHemoglobin
Samsun University420 enrolled1 locationNCT06857630